Cantor Fitzgerald lowered the firm’s price target on PTC Therapeutics (PTCT) to $76 from $80 and keeps an Overweight rating on the shares. The ...

In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on PTC Therapeutics (PTCT – Research Report), ...

In January 2024, the U.S. Bureau of Labor Statistics reported that U.S. manufacturers had over six hundred thousand vacancies. Two factors affecting the number of vacancies include not enough young ...